GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis

Published:2015-07 Issue:4 Volume:4 Page:370-376
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Wolinsky Jerry S.,Borresen T. Erik,Dietrich Dennis W,Wynn Daniel,Sidi Yulia,Steinerman Joshua R.,Knappertz Volker,Kolodny Scott

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference18 articles.

1. Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database;Al-Sabbagh;J. Neurol.,2008

2. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis;Bornstein;N. Engl. J. Med.,1987

3. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis;Boster;Ther. Adv. Neurol. Disord.,2011

4. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

5. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis;Comi;Ann. Neurol.,2011

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic review;Multiple Sclerosis Journal;2024-06-07

2. Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis;Journal of Neurology;2024-04-16

3. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30

4. Safety and Effectiveness of Cinnomer^® on Disease Characteristics, Depression, and Quality of Life of Patients with Multiple Sclerosis: A Phase IV, Post-marketing, Prospective, Multicenter Study;Archives of Iranian Medicine;2023-11-01

5. Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies;Frontiers in Neurology;2023-02-10